



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : C12N 1/38		A1	(11) International Publication Number: WO 92/06177 (43) International Publication Date: 16 April 1992 (16.04.92)
(21) International Application Number: PCT/US91/06380			(81) Designated States: AT (European patent), BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent).
(22) International Filing Date: 6 September 1991 (06.09.91)			
(30) Priority data: 593,930 5 October 1990 (05.10.90) US			Published <i>With international search report.</i>
(71) Applicant: LIFE TECHNOLOGIES, INC. [US/US]; 8717 Grovemont Circle, Gaithersburg, MD 20898 (US).			
(72) Inventor: FIKE, Richard, M. ; 9310 Hunting Valley Road, Clarence, NY 14031 (US).			
(74) Agents: GOLDSTEIN, Jorge, A. et al.; Sterne, Kessler, Goldstein & Fox, 1225 Connecticut Avenue, N.W., Suite 300, Washington, DC 20036 (US).			
(54) Title: METHOD FOR ENZYMATIC REGENERATION OF CELL CULTURE MEDIA AND MEDIA KITS THEREFOR			
(57) Abstract A multienzyme system capable of reducing waste products and synthesizing nutrients in a cell culture system is disclosed. In one embodiment, lactic dehydrogenase and leucine dehydrogenase are employed in conjunction with amino acid precursors and a recycling co-factor to achieve the synthesis of amino acids and a reduction in the levels of ammonia and lactic acid. The multienzyme system of the invention may be added directly to the cell culture system or it may be microencapsulated. Alternatively, the invention may be utilized in conjunction with a container unit in which cell culture medium contacts the multienzyme system external to the main culture vessel compartment.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU+	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE*	Germany	MC	Monaco	US	United States of America

+ Any designation of "SU" has effect in the Russian Federation. It is not yet known whether any such designation has effect in other States of the former Soviet Union.

Title of the Invention**METHOD FOR ENZYMATIC REGENERATION OF CELL CULTURE
MEDIA AND MEDIA AND KITS THEREFOR**Field of the Invention

5 This invention relates to methods of regulating and reducing the build-up of cellular waste products in cell culture systems, with concomitant synthesis of nutrients.

Background of the Invention

10 Cultured cells catabolize certain nutrients including carbon sources, amino acids, and vitamins. The cells undergo cell division and produce useful cellular products such as monoclonal antibodies, as well as waste products such as ammonia and lactic acid. 15 However, the accumulation of waste products and depletion of nutrients limits the functional life-span of a cell culture. In batch culture, cell death occurs after minimal levels of nutrients have been exhausted and/or intolerable levels of waste products have accumulated. 20 Various solutions to the build-up of waste products and depletion of nutrients have been attempted.

25 Continuous growth of cultures may be achieved by removing a portion of the culture and replacing it with fresh medium at regular intervals. This serves to remove waste products and replenish needed nutrients. In this method, fluid containing cells and media is continuously withdrawn from the cell culture container and replaced with fresh medium. Alternatively, in a perfusion system cells may be confined to the cell culture vessel such that only medium is withdrawn while fresh medium is added. 30

 However, the components of a cell culture system are not depleted uniformly. Thus, although the

-2-

perfused media may be depleted of three or four nutrients, it may contain adequate amounts of other components. The removal of these useful components by perfusion is uneconomical.

5 In these various systems, nutrient and waste levels are maintained by withdrawing "spent" medium and replacing with fresh medium. However, especially in large scale/high density cultures, perfusion of nutrients requires the costly transfer of large
10 volumes of media from the manufacturer to the culture facility, into the bioreactor, and finally to the product isolation facility. One way to minimize the cost and inconvenience of shipping large volumes of media is by the use of concentrates of tissue culture
15 media. However, concentrates need to be reconstituted with water prior to addition to the cultures and large volumes of spent media are generated.

20 Perfusion is associated with other disadvantages. For example, perfusion systems are susceptible to plugging by cells which must be separated from spent culture media. This is a significant concern for high density cultures since prodigious amount of fluids must be exchanged, sometimes greater than one culture volume per day. In addition, cell products must be isolated from the large volumes of spent culture media generated, and after products are isolated, large volumes of spent culture media must be disposed of.
25

30 Absorption technology has been advocated for removal of the waste product ammonia (Gordon, A., Greenbaum, M., Marantz, L., MacArthur, M. and Maxwell, M., "A Sorbent Based Low Volume Recirculating Dialysate System", Trans. Amer. Soc. Artif. Int. Organs 15:347-352, 1969)). Although this system eliminates ammonia, nutrient levels are not affected.
35 In addition, in-place regeneration of the adsorptive agent, zirconium phosphate, is difficult after the agent is saturated with ammonia. Reverse osmosis

-3-

systems again offer only toxin reduction capabilities with no means of increasing nutrient levels.

Thus, it would be an obvious benefit to the practice of cell culture if nutrients and waste products could be maintained within desired levels without the need for perfusion of large volumes of media.

Summary of the Invention

According to the invention, a multienzyme system permits the synthesis of nutrients, such as amino acids, and reduction of waste products, such as ammonia and lactic acid in cell culture systems. In a preferred embodiment, lactate dehydrogenase converts lactate to pyruvate in the presence of the co-factor NAD⁺. Leucine dehydrogenase converts α -keto acids to corresponding amino acids in the presence of NADH, which is generated by the lactate dehydrogenase reaction. The co-factor recycles continuously in the presence of adequate levels of substrates.

The present invention provides a mechanism for converting deleterious waste products into nutrients otherwise depleted in the cell culture system. It can be applied to systems for maintaining the levels of amino acids and other components necessary for continuous growth of cells in culture. As a result, the productive life-span of cultured cells is prolonged.

Brief Description of the Figure

Figure 1. Figure 1 illustrates a representative multienzyme system.

Detailed Description of the Invention

5

According to the invention, a reduction in waste products and a concomitant synthesis of amino acids and/or other nutrients in a cell culture system can be achieved using a multienzyme system.

10

By "cell culture system" is meant a system of growing cells in vitro in a culture vessel. Although the system is not limited to any particular culture vessel configuration or cell type, in a preferred embodiment, mammalian cells are grown in liquid culture media.

15

By "contacting," in reference to the cell culture medium, is meant the exposure of cell culture medium to the multienzyme system of the invention such that the enzymes of the multienzyme system (a) catalyze reactions between at least one component of the medium, such as a waste product, and a component of the multienzyme system, such as an amino acid precursor, and (b) regenerate the recycling co-factor of the multienzyme system.

20

By "recycling co-factor" is meant a nonprotein substance essential for activity of an enzyme. In one embodiment of the present invention, nicotinamide adenine dinucleotide (NAD^+) is a co-factor. NAD^+ is capable of conversion to NADH by electron transfer.

25

In one embodiment of the invention, NAD^+ is generated by the action of leucine dehydrogenase on an amino acid precursor to form an amino acid. Lactic dehydrogenase converts lactate to pyruvate, and by this reaction regenerates the co-factor as NADH.

30

By "nutrient" is meant any biological compound essential for growth and/or division of cells in culture. In one embodiment of this invention, amino acids are nutrients. Non-amino acid compounds, such as pyruvate, are also nutrients.

35

5 By "nutrient precursor" is meant a compound capable of enzymatic conversion into a nutrient. In one embodiment of this invention, the amino acid precursors α -ketoisocaproate, α -ketoisovalerate and α -keto- β -methylvalerate are precursors of, respectively, leucine, valine and isoleucine. One or more of these precursors can be employed in the multi-enzyme system.

10 15 By "multienzyme system" is meant a plurality of cooperatively functioning biological components capable of achieving the synthesis of at least one nutrient, utilizing at least one waste product and at least one nutrient precursor. According to a preferred embodiment, the multienzyme system of this invention contains lactate dehydrogenase, leucine dehydrogenase, ADP, KCl, NAD⁺, α -ketoisocaproate, α -ketoisovalerate and α -keto- β -methylvalerate.

20 Enzymes useful in the multienzyme system of the invention can be tested and selected on the basis of the following eight factors:

25 1) Toxicity and required concentrations of enzymes and co-factors. At working concentrations, the required molecules must not be toxic or inhibitory to cell growth and/or to the synthesis of biological products of the cells.

30 2) Enzyme activity in cell culture media. Some enzymes are known to be inhibited by various amino acids which are major components of cell culture media.

3) The preferred species and isotype of the various enzymes. It is well known that enzymes from different species, as well as isotypes within a species, vary in their affinity for different substrates. For example, lactic dehydrogenases from beef heart exist in four forms, each having a

-6-

5 different affinity for lactate. These affinities differ from the affinity of skeletal muscle lactic dehydrogenase, for which pyruvate is the preferred substrate. Also, glutamine synthetase from sheep brain is less likely to be inhibited by amino acids than that from bacterial sources (Meth. Enzymol. 113: Section II (Glutamine), 1985).

10 4) Inactivation of enzyme systems by proteases and other components of the cell culture system. Numerous proteolytic and inhibitory molecules may be likely to affect enzyme performance in a cell culture system, especially at high density.

15 5) Physiological environment is important. Many mammalian cell cultures require media of essentially neutral pH and temperatures of $37\pm2^{\circ}\text{C}$, a point at which many native enzymes are unstable.

20 6) Priming concentrations of ammonia/lactate. These concentrations must be compatible with the cell culture system.

7) Sterilization of materials for microencapsulation. For use in a cell culture system, all components and phases of the microencapsulation process must be sterile.

25 8) The effect of reaction kinetics. The reaction of pyruvate to lactate is thermodynamically favored. This is not desired in cell culture.

30 One method of selecting a particular enzyme for use in the multienzyme system is to first identify in a cell culture the accumulation of an undesirable waste product. Once this product is identified, enzymes are selected that will convert the waste

5 product into another form, preferably a nutrient source for the cell culture. The enzymes may be used in combination with an appropriate co-factor, preferably a co-factor capable of continuously recycling in the presence of adequate levels of substrates. The identity of the co-factor will be determined by the requirements of the enzymes chosen and their particular substrates.

10 A representative multienzyme system is illustrated in Figure 1. This system meets the requirements enumerated above for use in a cell culture system.

15 In a preferred embodiment, the system employs two enzymes, lactic dehydrogenase and leucine dehydrogenase, and a recycling co-factor (NAD⁺/NADH). Lactate dehydrogenase converts lactate to pyruvate in the presence of NAD⁺. Leucine dehydrogenase converts α -ketoacids (α -ketoisocaproate, α -ketoisovalerate, and α -keto- β -methyl valerate) into corresponding amino acids (leucine, valine, and isoleucine, respectively) in the presence of NADH, which is generated by the lactate dehydrogenase reaction. The co-factor recycles continuously as long as adequate levels of lactate, ammonia, and an amino acid precursor are present.

20 In a cell culture, the multienzyme system achieves the synthesis of amino acids with concomitant decreases in the waste products ammonia and lactic acid.

25 In other embodiments, alanine can be produced by the reductive amination of pyruvate, and glutamine can be produced from glutamic acid by the action of glutamine synthetase.

30 The form of the invention is not limited to a soluble solution or microencapsulated enzymes. The

invention can be utilized in conjunction with a container unit, wherein some or all of the cell culture medium is exposed to the multienzyme system within the container. For example, the multienzyme system can be placed within a hollow fiber unit, within a compartment separated by a semipermeable membrane. Cell culture (media and cells) passes through the center of the hollow fibers, and waste products from the media diffuse across the semipermeable membrane to contact the enzyme system. The waste products are converted into nutrients, such as amino acids, by the action of the multienzyme system, and these nutrients pass through the membrane to the cell culture.

In such a system, continuous automatically adjusted operation is possible. As the levels of waste products increase, the multienzyme system is triggered, whereas the multienzyme system is relatively inactive when waste products are at a low concentration, such as at the start of a new cell culture.

The container unit may be included as a component of a kit for convenient use with a cell culture system. The container unit of the kit may contain the enzymes of the multienzyme system. Other compartments of the multienzyme system, specifically a nutrient precursor and a recycling co-factor, can be supplied separately. The kit would also provide a means for contacting the cell culture with the multienzyme system. Optionally, the kit also provides a container having cell culture medium.

In one embodiment of the kit, the container means is a hollow fiber unit, and the enzymes are contained within a first compartment. One or more nutrient precursors and a recycling co-factor are added to the compartment containing the enzymes. The cell culture is contacted with the multienzyme system through a

-9-

second compartment which is separated from the first compartment by the semi-permeable membrane. The second compartment receives cell culture media, or media and cells, from the main culture vessel through, for example, a hollow tube.

5

In other embodiments of the kit, the first compartment of the container unit may contain the enzymes of the multienzyme system, and, in addition, one or more nutrient precursors and/or a recycling co-factor.

10

In another embodiment of the kit, separate containers are provided which hold, respectively, enzymes, co-factor(s) and nutrient precursors. Optionally, the enzymes may be provided in a microencapsulated form. The components are added to the culture system when appropriate on the basis of 15 the growth conditions of the culture.

15

One of skill in the art of cell culture is familiar with the various mechanical systems 20 associated with maintaining cell cultures. According to the invention, the multienzyme system can be conveniently incorporated into virtually any cell culture system. However, the invention is not intended to be limited to use with known cell culture 25 systems, and it is envisioned that as new and improved mechanical cell culture systems and apparatus are developed, spent cell culture media can be regenerated using the multienzyme system of the invention.

25

The following examples describe the application 30 of non-microencapsulated and microencapsulated multienzyme systems to cell culture systems.

30

Example 1

General Methods. The following enzymes and co-factors are added to a cell culture system, in the 35 order presented:

-10-

- A. Add lactic dehydrogenase to tissue culture medium.
- B. Reconstitute leucine dehydrogenase with "A".
- C. Add NAD⁺ to "B".
- 5 D. Add ADP to "C".
- E. Add KCl to "D".
- F. Add α -ketoisocaproate, α -ketoisovalerate and α -keto- β -methyl valerate to "E".
- 10 G. Filter "E" through a 0.22 μ non-pyrogenic Duropore membrane (Millipore Corp., Bedford, MA 01730).
- H. Store at 2-4°C until further use.

15 It is possible to either add the above reagents directly to the tissue culture medium for use or to formulate this as a concentrate in tissue culture medium which is then diluted into tissue culture media to provide the indicated final concentrations. (This may be desired if several types of cells or conditions are to be tested simultaneously.) It is also possible to adjust concentrations of reactants depending upon cell type, the desired rate of depletion of culture nutrients, and the rate of generation of waste products.

20

-11-

Example 2

Microencapsulation of Enzyme Systems

Reagents

A) Hexanediamine Solution

- 5 1. Add 0.378g of NaHCO₃ to 5ml deionized water.
2. Add 0.464g of 1,6-hexanediamine and dissolve.
3. Adjust pH to 9.0 with 5N HCl.
4. Add 2 ml of 50% polyethyleneimine.
5. Mix by inversion and re-adjust pH to 9.0.
- 10 6. Adjust volume to 10 ml with deionized water.
7. Filter through 0.22 μ Duropore membrane.
8. Store at 2°-4°C.

B) Organic Solvent

- 15 1. Mix 12 ml chloroform with 48 ml cyclohexane (1:4 v/v of chloroform: cyclohexane).
2. Add 0.9 ml Span 85 (Sorbitan Trioleate, Sigma Chemical Co., St. Louis, MO.)
3. Filter through 0.2 μ pore size Acrodisc CR (Gelman, sterilize by autoclaving).
- 20 4. Prepare fresh daily.
5. Store at 2°C-4°C.

C) Terephthaloyl Chloride Solution

- 25 1. Add 55 mg of terephthaloyl chloride to 15 ml organic solvent. Stir (or agitate gently) on ice for 30 minutes to dissolve.

-12-

2. Filter through 0.2μ pore size Acrodisc CR (Gelman, sterilize by autoclaving).

D) Tween-20 Solution (50%)

5 Dilute Tween-20 with equal volume of deionized, distilled H₂O. Adjust pH to 7.5 with 5N NaOH. Autoclave to sterilize. All glassware, (e.g. centrifuge tubes, flasks with covers, glass syringes, pipettes, etc.) must be autoclaved prior to use.

10 Procedure

1. Add lactic dehydrogenase to tissue culture medium (see Table 1).

2. Reconstitute leucine dehydrogenase with (1).

3. Filter sterilize (0.22μ Durapore membrane).

4. Under sterile conditions, mix equal volumes of (3) with hexanediamine solution. Keep on ice.

5. Vortex (vigorously) to emulsify, and while vortexing, add 15 ml of organic solvent. (Use 125 ml Erlenmeyer flask with cover).

6. Continue vortexing for one minute.

7. After one minute, add 15 ml of Terephthaloyl chloride solution. Continue vortexing for three minutes more.

8. After three minutes, add 30 ml organic solvent. Vortex 30 seconds.

9. Pour microcapsules into sterile glass centrifuge tube. Centrifuge at 1000 RPM for 2.5 minutes.

10. Discard supernatant under sterile conditions. Add 25 ml of 50% Tween 20, pH 7.5. Vortex to mix. Add 50 ml sterile deionized water, vortex and centrifuge at 2500 RPM for five minutes.

30 11. Wash several times with PBS.

12. Store at 4°C until use.

-13-

13. Prior to use, wash twice with media of choice for cell culture.
14. Example: 1.5 ml of enzyme solution (Step "2") yields approximately 3-4 ml of microcapsules which is sufficient to add to 15 ml of cell culture.
- 5 15. After the cell culture, (see below) and enzyme solution have been mixed together, the remaining components of the enzyme system need to be added, (i.e. NAD⁺, ADP, KCl, and the α -ketoacids). These may be added as concentrates (see chart) to the microencapsulated enzyme-cell culture mixture.

Example 3

15 Cell Culture Specifications

Use of enzyme regenerative technology has most relevance and utility at high cell densities where waste products are elevated, yielding triggering concentrations of ammonia and lactic acid. Also at 20 higher cell densities, less enzyme is required for a given unit/ml concentration. For hybridoma cells, good results have been observed with cells plated at 10^7 /ml. At this concentration, agitation is necessary to keep cells from clumping, as well as to assure 25 adequate oxygenation. Cells may be cultured in a bioreactor (oxygen, pH-controlled) with impeller design or in 12 well trays.

- 1) Cells should have viabilities greater than 90% and be in late log phase. It is preferable to avoid lag-phase cells.
- 30 2) Perform cell counts and adjust volume to contain 10^7 cells/ml.

-14-

- 3) It is preferable to supplement glutamine into the basal media at a 3x (6 mM) concentration (for a total of 8mM) to avoid glutamine insufficiency.
- 4) Prepare concentrates of NAD⁺, α -ketoacids, ADP, and KCl according to Table 1.
- 5) Prepare enzymes in tissue culture media, following steps A-H of Example 1.
- 10 6) Centrifuge cells and resuspend in tissue culture media. In order to have a final concentration of 1×10^7 cells/ml, it is important to take into account the dilution upon addition of the enzyme mixture (step 8).
- 7) Add cells to culture vessel or tray.
- 15 8) Immediately add enzyme mixture, NAD⁺, α -ketoacids, ADP and KCl. It is preferable to avoid alkaline conditions.
- 9) Place culture vessel or tray within a humidified chamber containing 5-10% CO₂/90%-95% air. This chamber may be placed upon a rotator at 20 approximately 150 RPM.
- 10) Incubate at 37°C.
- 11) Daily samples for determination of glucose, lactic acid, ammonia, viability, amino acid content and production capability (e.g. 25 monoclonal antibody) should be performed.

Results

30 Table 2 illustrates the synthesis of amino acids in a PBS aqueous phase (no cells) over 168 hours. As can be seen, isoleucine, leucine and valine increased significantly over this time period.

Tables 3 and 4 illustrate production levels of synthesized amino acids produced in a pH and oxygen-controlled bioreactor at high cell density,

-15-

5

with enzymes free in solution (Table 3) and microencapsulated (Table 4). Both experiments demonstrate that amino acid levels were increased by enzymatic means in cell culture and that microencapsulation is a viable alternative for separating enzymes from the cellular milieu.

10

Tables 5 and 6 illustrate the results of a high density 12 well tray assay. The presence of the enzyme mixture correlated with significantly higher cellular viability, monoclonal antibody production and less ammonia and lactic acid than without the enzyme mixture. The data illustrate that amino acid levels, as well as concentrations of lactic acid and ammonia, correlated with viability and monoclonal antibody production.

15

I. Levels of Amino Acids (Table 5)

20

Levels of isoleucine, leucine and valine, the synthesis of which is catalyzed by leucine dehydrogenase, are significantly elevated in all enzyme-containing cultures and media at all dilutions of enzyme tested (both skeletal muscle and bovine heart lactic dehydrogenase) compared to cultures lacking the enzyme system. Levels of these amino acids in cultures not containing the enzyme system are essentially depleted.

25

II. Levels of Ammonia/Lactic Acid (Table 6)

30

Levels of ammonia and lactic acid in most cultures were decreased in the presence of enzyme systems compared to cultures with no enzyme system. (The enzyme system was found to need titration to reach proper levels for lactate control relative to non-enzyme containing cultures). Ammonia levels are

-16-

observed to correlate quite closely with monoclonal antibody levels (see Table 6).

III. Cellular Viability (Table 6)

5 Appropriate enzyme systems could be found to significantly increase viability compared to non-enzyme containing cultures (e.g., skeletal muscle LDH/PFHM-II). Skeletal muscle LDH/RPMI-1640 + GMS-X and bovine heart LDH with PFHM-II also gave improved viability in culture.

10 IV. Monoclonal Antibody Production (Table 6)

15 The most important aspect to industry of a cell culture system is the affect on cellular production. As can be seen, the presence of properly titered enzyme systems in each category correlated with significant improvement in monoclonal antibody production.

TABLE 1
FORMULATION OF A MULTIZYME SYSTEM

Item	Source/type	Final Concentration in Cell Culture	Comment(s)
Leucine Dehydrogenase	Bacillus Species	1.25 units*/ml	Reconstitute lyophilized enzyme directly with media at 1:10 (wt.:vol.) in PBS.
L-Lactic Dehydrogenase	Bovine Heart Muscle LDH-1 (H4) <u>or</u> Rabbit Muscle Type XXXIX	17.5 units**/ml	1:5 (media) to 1:50 (PBS) concentrate.
α -ketoacids	α -Ketoisocaproate α -Ketoisovalerate α -Keto- β -Methyl Valerate	0.5 mg/ml	Add powder directly to media or prepare 100x in PBS.
NAD ⁺ (β -NAD) B-Nicotinamide Adenine Dinucleotide	Grade III, approx. 98%, from yeast	1.3 μ g/ml	1:100-1:500 (PBS) concentrate.
ADP (Adenosine 5'-Diphosphate)	Sodium salt, Grade III, 95-99%, from yeast ATP	10 μ g/ml	1:100-1:500 (PBS) concentrate.
KCl	Certified ACS	77 μ g/ml	1:100-1:500 (PBS) concentrate.

* One unit converts 1.0 μ mole of L-leucine to α -Ketoisocaproate per minute at pH 10.5 at 37°C.

** One unit reduces 1.0 μ mole of pyruvate to L-lactate per minute at pH 7.5 at 37°C.

- 18 -

TABLE 2

TIME COURSE OF SYNTHESIS OF VALINE, ISOLEUCINE AND LEUCINE
IN PBS WITH NO CELLS AT ROOM TEMPERATURE

<u>Amino Acid</u>	Amino Acid Concentrations (mg/l)					
	15 min	14.5 Hr	24 hr	63 hr	137 hr	165 hr
Valine	76	353	477	759	1048	1106
Isoleucine	73	351	477	773	1114	1197
Leucine	124	567	722	1067	1456	1551

TABLE 3

LEVELS (MG/L) OF VALINE, ISOLEUCINE AND LEUCINE IN A pH/O₂-
CONTROLLED BIOREACTOR AT HIGH CELL DENSITY
(10⁷ AE-1 HYBRIDOMA CELLS/ML)
ENZYMES FREE IN SUSPENSION

<u>Amino Acid</u>	Control	+E (24 Hrs)	-E (24 Hrs)	+E (48 Hrs)	-E (48 Hrs)
Valine	153	312	59	559	32
Isoleucine	156	226	22	473	2
Leucine	319	387	70	626	19

TABLE 4

LEVELS (MG/L) OF VALINE, ISOLEUCINE AND LEUCINE IN A pH/O₂-
CONTROLLED BIOREACTOR AT HIGH CELL DENSITY
(10⁷ AE-1 HYBRIDOMA CELLS/ML) WITH MICROENCAPSULATED ENZYMES

<u>Amino Acid</u>	Control	+E(24 Hrs)	-E(24 Hrs)	+E(48 Hrs)	-E(48 Hrs)
Valine	156	304	90	452	92
Isoleucine	154	231	46	337	34
Leucine	308	409	120	560	98

TABLE 5
PROFILE OF AMINO ACIDS (MG/L) SIGNIFICANTLY ALTERED
DURING HIGH DENSITY CELL CULTURE

Test	Alanine	Cystine	Glycine	Glutamine	Isoleucine	Leucine	Methionine	Valine
A	31	10	651	2	162	119	5	158
B	33	0	602	1	169	130	4	167
C	36	0	538	1	166	142	3	171
D	492	15	461	1	7	25	7	23
E	17	0	412	1	216	252	0	216
F	18	0	436	0	216	201	0	204
G	18	0	432	0	187	175	0	175
H	130	0	412	1	4	12	0	7
I	366	18	132	638	153	286	59	239
J	151	0	531	1	170	189	5	188
K	106	0	508	1	155	158	3	174
L	884	0	399	1	12	41	12	36
M	150	13	157	9	228	267	5	234
N	29	0	344	1	213	199	0	202
O	26	0	350	1	208	203	0	196
P	295	0	314	1	5	15	0	3
Q (PfHM-11 Control)	411	78	10	964	133	325	73	145
R (RPMI-1640 + GMs-X Control)	0	55	9	1000	41	48	9	19

TABLE 6
HIGH DENSITY CELL CULTURE ASSAY RESULTS
(96 HRS. EXCEPT AS NOTED)

Test	Enzyme System Dilution	Source of Lactic Dehydrogenase	Medium	% Viability (*24 hrs., **48 hrs.)	Lactate (g/L)	Glucose (g/L)	NH ₃ (mM)	Met (ug/mL)
A	0	Skeletal Muscle	PFHM-II	82**	0.05	0.55	6.22	260
B	1:5	Skeletal Muscle	PFHM-II	82**	0.05	0.45	6.23	254
C	1:10	Skeletal Muscle	PFHM-II	70**	0.05	0.50	6.85	216
D	---	---	PFHM-II	28**	0.10	0.50	6.90	179
E	0	Skeletal Muscle	RPMI-1640 + GMS-X	37**	0.05	0.45	3.61	185
F	1:5	Skeletal Muscle	RPMI-1640 + GMS-X	52**	0.10	0.55	4.22	168
G	1:10	Skeletal Muscle	RPMI-1640 + GMS-X	48**	0.05	0.35	4.36	136
H	---	---	RPMI-1640 + GMS-X	46**	0.10	0.55	5.99	143
I	0	Bovine Heart	PFHM-II	2*	1.85	0.65	19.6	47
J	1:5	Bovine Heart	PFHM-II	96*	0.05	0.55	7.96	294
K	1:10	Bovine Heart	PFHM-II	94*	0.05	0.30	7.64	309
L	---	---	PFHM-II	86*	0.10	0.50	16.9	167
M	0	Bovine Heart	RPMI-1640 + GMS-X	25**	0.75	0.50	20.5	59
N	1:5	Bovine Heart	RPMI-1640 + GMS-X	0**	0.05	0.40	6.2	151
O	1:10	Bovine Heart	RPMI-1640 + GMS-X	27**	0.05	0.50	5.4	182
P	---	---	RPMI-1640 + GMS-X	37**	0.10	0.60	15.5	102

- 21 -

5 Although the present invention has been described in connection with preferred embodiments, it is understood that modifications and variations are contemplated that do not depart from the spirit and scope of the invention. Such modifications and variations are considered to be within the scope of the invention and the appended claims.

We claim:

5 1. A method for controlling the concentration of at least one waste product in a cell culture system, said method comprising adding to said cell culture system a precursor of at least one nutrient, a first enzyme capable of catalyzing a reaction between said nutrient precursor and said waste product, a recycling co-factor, and a second enzyme capable of regenerating said co-factor.

10 2. The method of claim 1 wherein said waste product is ammonia and said nutrient precursor is an amino acid precursor.

15 3. The method of claim 2 wherein said amino acid precursor is chosen from the group containing α -ketoisocaproate, α -ketoisovalerate and α -keto- β -methylvalerate, and said first enzyme is leucine dehydrogenase.

20 4. The method of claim 1 wherein said second enzyme is lactic dehydrogenase.

5. The method of claim 1 wherein said recycling cofactor is NAD^+ .

25 6. The method of claim 1 further comprising adding to said cell culture system adenosine diphosphate.

7. The method of claim 1 wherein said first and second enzymes are added to said cell culture system in microencapsulated form.

8. A method of regenerating cell culture media, wherein said media contains at least one waste

- 23 -

product, said method comprising adding to said cell culture media at least one nutrient precursor, a first enzyme capable of producing a nutrient from said precursor and said waste product, a recycling co-factor, and a second enzyme capable of regenerating said co-factor.

9. The method of claim 8 wherein said nutrient precursor is an amino acid precursor and said waste product is ammonia.

10. The method of claim 9 wherein said amino acid precursor is chosen from the group consisting of α -ketoisocaproate, α -ketoisovalerate and α -keto- β -methylvalerate, said first enzyme is leucine dehydrogenase, and said recycling co-factor is NAD⁺.

11. The method of claim 10 wherein said second enzyme is lactic dehydrogenase.

12. The method of claim 9 further comprising adding to said cell culture system adenosine diphosphate.

13. The method of claim 8 wherein said first and second enzymes are added to said cell culture system in microencapsulated form.

14. A device for regenerating cell culture media comprising a container means containing at least one nutrient precursor, a first enzyme capable of converting said nutrient precursor to a nutrient, a recycling co-factor, a second enzyme capable of regenerating said co-factor, and a means for contacting said cell culture media with said nutrient precursor, said enzymes, and said co-factor.

- 24 -

15. The device of claim 14 wherein said nutrient precursor is an amino acid precursor.

16. The device of claim 15 wherein said second enzyme is lactic dehydrogenase.

5 17. The device of claim 14 wherein said recycling co-factor is NAD⁺.

10 18. The device of claim 15 wherein said amino acid precursor is chosen from the group consisting of α -ketoisocaproate, α -ketoisovalerate and α -keto- β -methyl valerate and said first enzyme is leucine dehydrogenase.

15 19. The device of claim 14 wherein said container means comprises a hollow fiber unit having at least two compartments separated by a semipermeable membrane, wherein said nutrient precursor, enzymes and co-factor are located in a first compartment, and said media is located in a second compartment.

20 20. A kit for regenerating cell culture media, wherein said kit comprises

a container unit (a) containing at least one enzyme capable of converting a nutrient precursor to a nutrient;

a container unit (b) containing at least one nutrient precursor;

25 a container unit (c) containing at least one recycling co-factor; and

a container unit (d) containing at least one enzyme capable of regenerating said co-factor.

30 21. The kit of claim 20 wherein said container unit (a) contains leucine dehydrogenase; said

- 25 -

5 container unit (b) contains at least one amino acid precursor chosen from the group consisting of α -ketoisocaproate, α -ketoisovalerate and α -keto- β -methylvalerate; said container unit (c) contains lactic dehydrogenase; and said container unit (d) contains NAD⁺.

22. The kit of claim 20 further comprising a container unit containing cell culture medium.

1/1




FIG. 1

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US91/06380

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶

According to International Patent Classification (IPC) or to both National Classification and IPC

IPC(5): C12N 1/38

USCL: 435/244

II. FIELDS SEARCHED

Minimum Documentation Searched ⁷

Classification System	Classification Symbols
U.S.CL	435/3, 69.2, 243, 244

Documentation Searched other than Minimum Documentation
to the Extent that such Documents are Included in the Fields Searched ⁸

Biosis "cell /tissue culture, waste product, lactic dehydrogenase, leucine dehydrogenase, enzyme, glutamic acid, amino acid precursor, pyruvate"

III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹

Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
Y	Biological abstract, vol. 98, issued 1983, Wandry et al., "Multienzyme systems in Membrane Reactors." see page 51916, Abstract No. 98,51907g.	1-10, 12-15, 17-22
Y	Trans. Amer. Soc. for Artificial Internal Organs, Vol XXIV, issued 1978, "Artificial Cells Microencapsulated Multienzyme" Chang et al. System for Converting Urea and Ammonia to Amino Acid Using α -Ketoglutaric and Glucose as substrate, pages 18-20, see entire document.	1-22
Y	US.A 4,891,310 (SHIMIZU ET AL.) 02 January 1990, see entire document.	14-22
Y	Applied Biochemistry and Biotechnology issued 1990, Cu et al., "Conversion of Ammonium or Urea into Essential Amino Acids, L-Leucine, L-Valine, and L-Isoleucine Using Artificial Cells containing an Immobilized Multienzyme system and Dextran-NAD ⁺ ." pages 115-124, see entire document	1, 2, 4-17

* Special categories of cited documents: ¹⁰

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"Z" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search

10 October 1991

International Searching Authority

ISA/US

Date of Mailing of this International Search Report

19 DEC 1991

Signature of Authorized Officer

Jane Williams